Back to Search
Start Over
Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers.
- Source :
-
Diabetes & metabolic syndrome [Diabetes Metab Syndr] 2020 Jul - Aug; Vol. 14 (4), pp. 283-287. Date of Electronic Publication: 2020 Apr 09. - Publication Year :
- 2020
-
Abstract
- Background and Aims: COVID-19 is already a pandemic. Emerging data suggest an increased association and a heightened mortality in patients of COVID-19 with comorbidities. We aimed to evaluate the outcome in hypertensive patients with COVID-19 and its relation to the use of renin-angiotensin system blockers (RASB).<br />Methods: We have systematically searched the medical database up to March 27, 2020 and retrieved all the published articles in English language related to our topic using MeSH key words.<br />Results: From the pooled data of all ten available Chinese studies (n = 2209) that have reported the characteristics of comorbidities in patients with COVID-19, hypertension was present in nearly 21%, followed by diabetes in nearly 11%, and established cardiovascular disease (CVD) in approximately 7% of patients. Although the emerging data hints to an increase in mortality in COVID-19 patients with known hypertension, diabetes and CVD, it should be noted that it was not adjusted for multiple confounding factors. Harm or benefit in COVID-19 patients receiving RASB has not been typically assessed in these studies yet, although mechanistically and plausibly both, benefit and harm is possible with these agents, given that COVID-19 expresses to tissues through the receptor of angiotensin converting enzyme-2.<br />Conclusion: Special attention is definitely required in patients with COVID-19 with associated comorbidities including hypertension, diabetes and established CVD. Although the role of RASB has a mechanistic equipoise, patients with COVID-19 should not stop these drugs at this point of time, as recommended by various world organizations and without the advice of health care provider.<br />Competing Interests: Declaration of competing interest We hereby declare that we have no conflict of interest related to this article.<br /> (Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.)
- Subjects :
- Angiotensin Receptor Antagonists adverse effects
Angiotensin Receptor Antagonists therapeutic use
Angiotensin-Converting Enzyme 2
Angiotensin-Converting Enzyme Inhibitors adverse effects
Angiotensin-Converting Enzyme Inhibitors therapeutic use
Animals
Antihypertensive Agents adverse effects
COVID-19
Cardiovascular Diseases epidemiology
China epidemiology
Coronavirus Infections mortality
Diabetes Mellitus epidemiology
Humans
Hypertension epidemiology
Mice
Pandemics
Peptidyl-Dipeptidase A physiology
Pneumonia, Viral mortality
PubMed
Renin-Angiotensin System physiology
SARS-CoV-2
Antihypertensive Agents therapeutic use
Betacoronavirus
Comorbidity
Coronavirus Infections epidemiology
Hypertension drug therapy
Pneumonia, Viral epidemiology
Renin-Angiotensin System drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1878-0334
- Volume :
- 14
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Diabetes & metabolic syndrome
- Publication Type :
- Academic Journal
- Accession number :
- 32283499
- Full Text :
- https://doi.org/10.1016/j.dsx.2020.03.016